| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02941510 Details | 2017-03-13 Interventional | 3 | 0 | Budesonide Altitude Sickne… | Stopped prior to enrollment per PI and DSMB decision. - | |||
| NCT01987960 2012-004982-41 Details | 2017-03-13 Interventional | 3 | 417 | Brexpiprazole Stress Disorder… Stress Disorder… PTSD Post-traumatic … | The study was terminated due to challenges with patient eligibility; the decision to terminate
was not based on any safety concerns As the study was terminated limited efficacy and safety data were collected from the randomized patients. The data are descriptive and the primary and key secondary efficacy analyses were not done. | |||
| NCT00811967 Details | 2017-03-13 Interventional | 3 | 50 | Interferon-alph… Peginterferon a… Ribavirin Disease Progres… Fibrosis Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Liver Cirrhosis | - - | |||
| NCT00560352 Details | 2017-03-13 Interventional | 1 | 16 | Bortezomib Dasatinib Dexamethasone Multiple Myelom… Neoplasms, Plas… | - The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase. | |||
| NCT00383942 Details | 2017-03-13 Interventional | 4 | 80 | Misoprostol Cesarean Sectio… | Change in treatment plan for this population terminated the project This trial was terminated prematurely due to a department policy change regarding inductions of labor. | |||
| NCT02538146 Details | 2017-03-10 Interventional | 1 | 3 | Acetylcarnitine Pancreatitis Pancreatitis, C… Chronic Pancrea… | Older participants could not tolerate the acidity of the product and withdrew. - | |||
| NCT02341079 Details | 2017-03-10 Interventional | 2/3 | 0 | Bupivacaine Osteoarthritis Osteoarthritis,… Arthritis, Dege… Osteoarthrosis Osteoarthrosis … | Principal no longer interested in conducting study - | |||
| NCT01933022 2012-000101-69 Details | 2017-03-09 Interventional | 4 | 1 | Leuprolide Prostatic Neopl… Metastatic Pros… | Termination due to high current screen rate failure and unreliable PSA mRNA assay. - | |||
| NCT01631630 Details | 2017-03-09 Interventional | 2 | 16 | Pioglitazone Alcohol Drinkin… Alcohol-Related… Alcoholism Alcohol Depende… Stress | The study was closed to recruitment due to feasibility problems. This study was terminated early, so the number of subjects analyzed is small. | |||
| NCT00883116 2008-007167-16 Details | 2017-03-09 Interventional | 3 | 551 | Albumin-Bound P… Doxorubicin Paclitaxel Endometrial Neo… Endometrial Can… | Interim analysis results showed that ixabepilone did not improve survival compared with control
chemotherapies. This study was terminated per Data Monitoring Committee. Results from an interim analysis showed that there was no favorable benefit/risk ratio with ixabepilone and that ixabepilone did not improve survival compared with control chemotherapies. | |||
| NCT02723838 Details | 2017-03-07 Interventional | 1 | 0 | Gemcitabine Carcinoma Carcinoma, Tran… Urinary Bladder… Muscle-invasive… | Company has reprioritized clinical plans to focus on later-stage studies. - | |||
| NCT02144012 Details | 2017-03-07 Interventional | 3 | 49 | Ado-Trastuzumab… Docetaxel Maytansine Trastuzumab Breast Neoplasm… Metastatic Brea… | - Due to early termination of the study only limited data from a small subset (49) of the originally planned study population size (561) are available and were too limited to perform originally planned efficacy analyses as specified in the protocol. | |||
| NCT02086487 Details | 2017-03-07 Interventional | 4 | 98 | Nilotinib Leukemia, Myelo… Myeloid Leukemi… | Because of many unseen obstacles resulted in poor accrual, study is terminated. - | |||
| NCT01457846 Details | 2017-03-07 Interventional | 2 | 960 | Paclitaxel Stomach Neoplas… Gastric Cancer Gastro-oesophag… | - Prompted by slow recruitment, AZ and the SRC instigated unscheduled analysis of the efficacy and tolerability. It was concluded that the study was unlikely to meet its primary objective. Enrolment ceased and the study closed. | |||
| NCT01884675 Details | 2017-03-06 Interventional | 3 | 33 | Ambrisentan Hypertension Hypertension, P… | - - | |||
| NCT02811484 Details | 2017-03-03 Interventional | 4 | 0 | Dapagliflozin Exenatide Diabetes Mellit… Diabetes Mellit… Overweight | Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM,
including those on concomitant insulin therapy. - | |||
| NCT00510627 Details | 2017-03-03 Interventional | 4 | 0 | Irinotecan Oxaliplatin Liver Neoplasms Neoplasm Metast… Liver Neoplasm Metastatic Live… Secondary Liver… | Boston Scientific has decided to close the Study. - | |||
| NCT02200562 Details | 2017-03-01 Interventional | 1 | 6 | Dabrafenib Ipilimumab Melanoma Stage III or IV… | BMS withdrew support and required this trial to stop enrolling; Phase II portion never began,
only a Phase I trial. - | |||
| NCT01731587 2012-001435-31 Details | 2017-02-28 Interventional | 1 | 0 | Cyclophosphamid… Carcinoma, Non-… Lung Neoplasms Non-small Cell … | The objectives of this trial are no longer deemed appropriate for the clinical development of
L-BLP25 therefore this trial is withdrawn - | |||
| NCT02638129 Details | 2017-02-27 Interventional | 4 | 67 | Bupropion Naltrexone Cardiovascular … Obesity | - As this study was prematurely terminated, analysis of the primary and secondary outcome measures was not performed and analysis of safety was limited in scope. |